ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Trading 12-17 13:46:51 EST

41.65

-0.59

-1.40%

High42.93	Low41.53	Vol185.30K
Open42.46	D1 Closing42.24	Amplitude3.31%
Mkt Cap2.39B	Tradable Cap1.61B	Total Shares57.44M
T/O7.83M	T/O Rate0.48%	Tradable Shares38.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":41.65,"timestamp":1765997206591,"preClose":42.24,"halted":0,"volume":185297,"delay":0,"floatShares":38696732,"shares":57438900,"eps":1.791771,"marketStatus":"Trading","change":-0.59,"latestTime":"12-17 13:46:51 EST","open":42.46,"high":42.93,"low":41.53,"amount":7826901.735204999,"amplitude":0.033144,"askPrice":41.67,"askSize":219,"bidPrice":41.62,"bidSize":33,"shortable":3,"etf":0,"ttmEps":1.791771,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766005200000},"marketStatusCode":2,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":42.24,"preHourTrading":{"tag":"盘前","latestPrice":42.77,"preClose":42.24,"latestTime":"09:29 EST","volume":8,"amount":340,"timestamp":1765981770118},"postHourTrading":{"tag":"盘后","latestPrice":42.24,"preClose":42.24,"latestTime":"18:02 EST","volume":7332,"amount":309702.57,"timestamp":1765926177709},"volumeRatio":0.338609,"impliedVol":0.5765,"impliedVolPercentile":0.372},"requestUrl":"/m/hq/s/ODD/tweets","defaultTab":"tweets","newsList":[{"id":"2591250996","title":"Highlighting December 2025's Growth Leaders With Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2591250996","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591250996?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:05","pubTimestamp":1765818349,"startTime":"0","endTime":"0","summary":"As the United States stock market grapples with concerns over an AI bubble, technology shares have been under pressure, causing declines in major indices like the Nasdaq and Dow Jones Industrial Average. In such a volatile environment, companies with strong growth potential and high insider ownership can offer investors a sense of stability and alignment of interests between management and shareholders.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eton/eton-pharmaceuticals/news/highlighting-december-2025s-growth-leaders-with-insider-owne","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eton/eton-pharmaceuticals/news/highlighting-december-2025s-growth-leaders-with-insider-owne","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["STUB","BK4096","BK4170","LU1861220033.SGD","BK4213","BK4585","BK4007","IE00B19Z9P08.USD","PROP","BK4555","LU2460026573.USD","LU0605514214.HKD","LU0231459107.USD","LU0594300419.USD","LU2087625088.SGD","LU2360106780.USD","LU0056508442.USD","NIU.AU","ODD","BK4558","IE00B19Z9Z06.USD","BK4187","LU0650527681.SGD","SES","BK4543","LU0082616367.USD","KRMN","LU0594300179.USD","BK4539","LU2063271972.USD","SMCI","ATAT","BK4212","WEST","ETON","NIU","BK4023","LU0274383776.USD","LU0353189763.USD","BK4142","IE00B894F039.SGD","ALAB","APP","BK4608","BK4183","CRDO","BK4141","IE00BZ9MQY76.HKD","BK4192","IE0009354923.USD"],"gpt_icon":1},{"id":"2591677686","title":"ODDITY Tech Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2591677686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591677686?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:18","pubTimestamp":1765567080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 14:18 ET (19:18 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2590516616","title":"Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516616","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516616?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458300,"startTime":"0","endTime":"0","summary":"Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and onlypotent, highly selective inhibitor of human 12-LOX in clinical testing,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203875/0/en/Cadrenal-Therapeutics-Acquires-VLX-1005-a-First-in-Class-Phase-2-12-LOX-Inhibitor-for-Patients-with-Heparin-Induced-Thrombocytopenia-HIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4007","BK4539","HIT","TE","BK4096","IE0009354923.USD","BK4173","LENZ","BK4139","ODD"],"gpt_icon":0},{"id":"2590166035","title":"Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590166035","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590166035?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biop","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203828/0/en/Praxis-Precision-Medicines-Announces-Plans-to-File-an-NDA-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies-in-Early-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ODD","PRAX","CNS","BK4200","BK4561","BK4183","LU0320765992.SGD","LU0889565916.HKD","ASO","BK4135","LU0109394709.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"2590343065","title":"Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343065","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343065?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281600,"startTime":"0","endTime":"0","summary":"ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202225/0/en/Senti-Bio-Announces-Updated-SENTI-202-Clinical-Data-from-Ongoing-Phase-1-Trial-in-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-Patients-Demonstrating-Deep-MRD-Negative-Durable-Com.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","CR","BK4183","LD","BK4588","ORR","IE00BYQQ9H92.USD","BK4109","ODD","BK4533","MTD","BK4024","LU2463526074.USD","BK4548","IE00BFXG0V08.USD","LU1093756168.USD","BK4121","IE0009354923.USD","LU2413666699.HKD","ASH","AEI","LU0347712357.USD","LU2413666426.HKD","BK4563","LU1093756325.SGD","BK4161","LU2211817866.USD","BK4585","LU1721428933.USD"],"gpt_icon":0},{"id":"2589018258","title":"Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2589018258","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589018258?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149600,"startTime":"0","endTime":"0","summary":"LOS ANGELES, CA, Dec.  07, 2025  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201157/0/en/Immix-Biopharma-Announces-Pricing-of-Upsized-100-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","LU1791710400.SGD","LU2028103732.USD","LU2357305700.SGD","LU0912757837.SGD","LU0106831901.USD","LU0882574139.USD","LU2347655156.SGD","LU1720051017.SGD","LU1791710582.SGD","BK4504","LU1244550577.SGD","LU1720051108.HKD","LU2023251221.USD","LU0528227936.USD","BK4183","LU0267386448.USD","LU1989772840.SGD","LU0225283273.USD","LU1668664300.SGD","BK4581","LU2271345857.HKD","LU1244550494.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1363072403.SGD","IE0009354923.USD","LU0795875169.SGD","LU0158827948.USD","LU0320765646.SGD","LU1732799900.SGD","LU1162221912.USD","LU2089284900.SGD","BK4588","ODD","LU0795875086.SGD","BK4534","LU0098860793.USD","BK4516","LU0971096721.USD","LU1074936037.SGD","LU1548497426.USD","LU0557290698.USD","LU0106261372.USD","LU2111349929.HKD","LU0314104364.USD","LU2089283258.USD","LU1244550221.USD","LU1989772923.USD"],"gpt_icon":0},{"id":"2589801826","title":"At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801826?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:15","pubTimestamp":1765149300,"startTime":"0","endTime":"0","summary":"– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201155/0/en/At-ASH-2025-Oral-Presentation-Immix-Biopharma-Reports-Positive-Phase-2-NXC-201-Results-Advancing-Toward-BLA-Submission-as-a-Potentially-First-and-Best-in-Class-Therapy-for-relapsed.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXC","IE0009354923.USD","BK4109","LU1169590202.USD","BK4230","CR","ASH","BK4572","BK4022","LU1169589451.USD","LU2463526074.USD","ODD","AL","KOL","IE0034390439.USD","CAR","BK4183","BK4161","BK4104","IE00B19Z6F94.USD"],"gpt_icon":0},{"id":"2588062470","title":"Cboe to Offer Nearly 24-Hour Trading for Russell 2000 Options, Expanding Global Access to U.S. Small-Cap Equities","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062470","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588062470?lang=en_us&edition=fundamental","pubTime":"2025-12-03 07:47","pubTimestamp":1764719220,"startTime":"0","endTime":"0","summary":"Russell 2000 Index  options to trade nearly 24x5 during Cboe's Global Trading Hours. Expansion that may allow European and Asia-Pacific traders to more easily manage U.S. small-cap exposure. Initiative is part of Cboe's ongoing efforts to expand global access to its proprietary U.S. equity index options. CHICAGO, Dec. 3, 2025 /PRNewswire/ -- Cboe Global Markets, Inc. , the world's leading derivatives and securities exchange network, today announced plans to extend trading hours for its Russell 2000 Index  options suite to nearly 24 hours a day, five days a week, beginning February 9, 2026.The Russell 2000 Index measures the performance of U.S. small-cap equities across sectors and has long served as a barometer of small-cap performance. As of the end of November, average daily volume in Cboe's RUT options has grown to nearly 75 thousand contracts, up 66% compared to full year 2022, as more traders look to manage risk and implement daily options strategies. The Russell 2000 Index has","market":"sg","thumbnail":"https://mma.prnewswire.com/media/622233/5652355/Cboe_GM_New_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/622233/5652355/Cboe_GM_New_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/cboe-to-offer-nearly-24-hour-trading-for-russell-2000-options-expanding-global-access-to-us-small-cap-equities-302631100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7024","BK4139","BK7043","BK4183","GTH","SPX.AU","IE0009354923.USD","GTH.AU","ODD"],"gpt_icon":0},{"id":"2586420654","title":"Unicycive Therapeutics to Participate in Upcoming Investor Events in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420654?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:05","pubTimestamp":1764072300,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., Nov.  25, 2025  (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194215/0/en/Unicycive-Therapeutics-to-Participate-in-Upcoming-Investor-Events-in-December.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","UNCY","BK4183","BK4139","BK4539","ODD"],"gpt_icon":0},{"id":"2585144756","title":"Oddity Tech's Methodiq Telehealth Platform to be Key Driver for Stock Going Ahead, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2585144756","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585144756?lang=en_us&edition=fundamental","pubTime":"2025-11-21 23:53","pubTimestamp":1763740393,"startTime":"0","endTime":"0","summary":"Oddity Tech's  potential success of the Methodiq app-based telehealth platform will be a key driver for the stock going ahead, Morgan Stanley analysts said in a Friday note.Analysts said that while a challenging consumer environment has pressured beauty stocks and fears loom around a recent slowdown in Oddity Tech's US credit card data, the company posted \"solid\" Q3 upside and that its near-term delivery remains \"impressive\".Oddity Tech reported Q3 adjusted earnings late Wednesday of $0.40 per diluted share, beating a FactSet analyst poll of $0.36. Revenue in the three months ended Sept. 30 was $147.9 million compared with a FactSet survey of $145.5 million.Morgan Stanley lowered the stock's rating to $49 from $61 to reflect a more uncertain US environment. It retained an equalweight rating.Price: 38.60, Change: -0.97, Percent Change: -2.45","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0234570918.USD","LU2023251221.USD","LU2089283258.USD","IE00BKVL7J92.USD","LU1989772923.USD","BK4516","LU0006306889.USD","LU0557290698.USD","LU1732800096.USD","BK4504","BK4183","LU0314104364.USD","LU1720051108.HKD","LU1791710400.SGD","LU1989772840.SGD","BK4585","LU2089284900.SGD","LU1162221912.USD","LU1791710582.SGD","LU1548497426.USD","LU0106831901.USD","LU0320765646.SGD","LU0158827948.USD","LU0098860793.USD","LU1732799900.SGD","LU0795875169.SGD","LU0106261372.USD","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0528227936.USD","BK4127","LU0158827781.USD","LU1244550221.USD","BK4581","LU2028103732.USD","LU0795875086.SGD","LU2111349929.HKD","LU2357305700.SGD","LU0971096721.USD","LU2133065610.SGD","ODD","LU1720051017.SGD","LU0882574139.USD","IE0009354923.USD","LU1244550577.SGD","LU0267386448.USD","LU1363072403.SGD","LU0912757837.SGD","LU0225283273.USD","BK4534"],"gpt_icon":0},{"id":"1109414107","title":"Stock Track | ODDITY Tech Plummets 5.21% as Multiple Analysts Slash Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1109414107","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109414107?lang=en_us&edition=fundamental","pubTime":"2025-11-21 23:00","pubTimestamp":1763737222,"startTime":"0","endTime":"0","summary":"Shares of ODDITY Tech Ltd. (ODD) plunged 5.21% in pre-market trading on Friday, as several prominent Wall Street analysts significantly lowered their price targets for the company. The sharp decline...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ODD"],"gpt_icon":0},{"id":"1166545433","title":"Stock Track | ODDITY Tech Plummets 5.21% as Multiple Analysts Slash Price Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=1166545433","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166545433?lang=en_us&edition=fundamental","pubTime":"2025-11-21 23:00","pubTimestamp":1763737222,"startTime":"0","endTime":"0","summary":"ODDITY Tech Ltd. (ODD) shares plummeted 5.21% in Friday's pre-market trading session following a series of price target cuts from major financial institutions. The beauty and wellness company faced a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ODD"],"gpt_icon":0},{"id":"2585146296","title":"ODDITY Tech Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2585146296","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585146296?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:17","pubTimestamp":1763734620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 09:17 ET (14:17 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","ODD"],"gpt_icon":0},{"id":"2585711706","title":"Morgan Stanley Lowers Price Target on ODDITY Tech to $49 From $61, Keeps Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2585711706","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585711706?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:55","pubTimestamp":1763726154,"startTime":"0","endTime":"0","summary":"ODDITY Tech (ODD) has an average rating of overweight and mean price target of $66.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD"],"gpt_icon":0},{"id":"2585843117","title":"Bath & Body Works, Inc. : Morgan Stanley  Cuts to Equal-Weight From Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2585843117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585843117?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:28","pubTimestamp":1763724493,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WW1LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4585","BK4200","BK4183","BK4588","BBWI","IE0009354923.USD","BK4551"],"gpt_icon":0},{"id":"2585117846","title":"Bath & Body Works, Inc. : Morgan Stanley  Cuts Target Price to $18.00 From $43.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117846?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:28","pubTimestamp":1763724493,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WW1LT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","ODD","BK4551","BBWI","BK4200","BK4183","BK4588","IE0009354923.USD"],"gpt_icon":0},{"id":"2585011781","title":"Oddity Tech Ltd : Morgan Stanley  Cuts Target Price to $49.00 From $61.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2585011781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585011781?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:28","pubTimestamp":1763724493,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WW1LT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4588","BK4200","BK4183","BK4551","BK4585","BBWI","IE0009354923.USD"],"gpt_icon":0},{"id":"2585117841","title":"ODDITY Tech Price Target Maintained With a $72.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117841","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117841?lang=en_us&edition=fundamental","pubTime":"2025-11-21 18:28","pubTimestamp":1763720880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 05:28 ET (10:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2585143951","title":"Oddity price target lowered to $46 from $64 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585143951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585143951?lang=en_us&edition=fundamental","pubTime":"2025-11-21 18:20","pubTimestamp":1763720453,"startTime":"0","endTime":"0","summary":"Barclays analyst Lauren Lieberman lowered the firm’s price target on Oddity (ODD) to $46 from $64 and keeps an Equal Weight rating on the shares. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oddity-price-target-lowered-to-46-from-64-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oddity-price-target-lowered-to-46-from-64-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","IE0009354923.USD","ODD"],"gpt_icon":0},{"id":"1153970633","title":"Post-Bell | US Stocks Slump With Nasdaq Down 2%; Tesla Falls 2%; Nvidia Drops 3%; Micron Sinks 11%; SanDisk Tumbles 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153970633","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153970633?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:00","pubTimestamp":1763679600,"startTime":"0","endTime":"0","summary":"Wall Street stocks slid on Thursday in a sharp reversal from an early rally, as technology gains faded after a boost from Nvidia's earnings and U.S. jobs data muddied the labor market outlook.Market...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"884ac5cf4fed827582c221e8bac70a93","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORCL","CRWV","PANW","ODD","IBM","REGN","J-W","NVDA","CSCO","CIFR","EXAS","SMCI","WMT","MU","PLTR","TSLA","MSFT",".SPX",".IXIC","ABT","AMZN","GOOGL","SNDK","BBWI","PACS",".DJI","AMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":0.0906},{"period":"3month","weight":-0.3236},{"period":"6month","weight":-0.3944},{"period":"1year","weight":-0.1511},{"period":"ytd","weight":0.0052}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction